ArticlePloS one2017
Platelet-, monocyte-derived and tissue factor-carrying circulating microparticles are related to acute myocardial infarction severity.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed.
- Utility of novel T-cell-specific extracellular vesicles in monitoring and evaluation of acute GVHD.International journal of hematology · 2021Trial
- Ticagrelor attenuates the increase of extracellular vesicle concentrations in plasma after acute myocardial infarction compared to clopidogrel.Journal of thrombosis and haemostasis : JTH · 2020Trial
- Trial
- Evaluation of 3 commercial assays for the measurement of tissue factor activity in human plasma.Research and practice in thrombosis and haemostasis · 2026Article
- Insights into the Versatile Role of Extracellular Vesicles in the Treatment of CNS Disorders.Molecular neurobiology · 2025Review
- A prospective cohort study on prognostic implications of serum platelet derived microparticles levels in acute cerebral infarction.Scientific reports · 2025Article
- Thromboinflammatory Biomarkers in Lymphomas: Linking Inflammation to Thrombosis Risk.International journal of molecular sciences · 2025Article
- Integrative Machine Learning of Glioma and Coronary Artery Disease Reveals Key Tumour Immunological Links.Journal of cellular and molecular medicine · 2025Article
- Assessment of frailty in patients with advanced chronic kidney disease, and the role of microvesicles: A single-center study.PloS one · 2025Article
- Platelets and Their Role in Immunity: Formation, Activation and Activity, and Biologically Active Substances in Their Granules and Extracellular Vesicles.International journal of inflammation · 2025Review
- Plasma tissue factor as a promising marker in multiple sclerosis: Evidence from a two-sample Mendelian randomization study.Translational neuroscience · 2025Article
- Global requirements for manufacturing and validation of clinical grade extracellular vesicles.The journal of liquid biopsy · 2024Review
- Challenges with measuring tissue factor antigen and activity in human plasma.Blood vessels, thrombosis & hemostasis · 2024Review
- Predictive indicators in peripheral blood and left atrium blood for left atrial spontaneous echo contrast in atrial fibrillation patients.BMC cardiovascular disorders · 2024Article
- Platelet and Monocyte Microvesicles as Potential Biomarkers of COVID-19 Severity: A Cross-Sectional Analysis.Annals of laboratory medicine · 2024Article
- Progress in extracellular vesicle homeostasis as it relates to cardiovascular diseases.Journal of physiology and biochemistry · 2024Review
- Extracellular vesicles: mechanisms and prospects in type 2 diabetes and its complications.Frontiers in endocrinology · 2024Review
- Article
- The Effects of Statins, Ezetimibe, PCSK9-Inhibitors, Inclisiran, and Icosapent Ethyl on Platelet Function.International journal of molecular sciences · 2023Review
- The Effect of Extracellular Vesicles on Thrombosis.Journal of cardiovascular translational research · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveCirculating microparticles (cMPs) are phospholipid-rich vesicles released from cells when activated or injured, and contribute to the formation of intracoronary thrombi. Tissue factor (TF, CD142) is the main trigger of fibrin formation and TF-carrying cMPs are considered one of the most procoagulant cMPs. Similar types of atherosclerotic lesions may lead to different types of AMI, although the mechanisms behind are unresolved. Therefore, we aimed to investigate the phenotype of cMPs found in plasma of ACS patients and its relation to AMI severity and thrombotic burden.
methodsIn a cross-sectional study, two hundred patients aged 75±4 years were included in the study 2-8 weeks after suffering an AMI. Annexin V positive (AV+)-cMPs derived from blood and vascular cells were measured by flow cytometry. Plasma procoagulant activity (TF-PCA) was measured through a chromogenic assay.
resultsSTEMI patients (n = 75) showed higher levels of platelet-derived cMPs [CD61+/AV+, CD31+/AV+, CD42b+/AV+ and CD31+/CD42b+/AV+, P = 0.048, 0.038, 0.009 and 0.006, respectively], compared to NSTEMI patients (n = 125). Patients who suffered a heart failure during AMI (n = 17) had increased levels of platelet (CD61+)-and monocyte (CD14+)-derived cMPs carrying TF (CD142+) (P<0.0001 and 0.004, respectively). Additionally, NYHA class III (n = 23) patients showed higher levels of CD142+/AV+, CD14+/AV+ and CD14+/CD142+/AV+ cMPs than those in class I/II (P = 0.001, 0.015 and 0.014, respectively). The levels of these cMPs positively correlated with TF-PCA (r≥0.166, P≤0.027, all).
conclusionsPlatelets and monocytes remain activated in AMI patients treated as per guidelines and release cMPs that discriminate AMI severity. Therefore, TF-MPs, and platelet- and monocyte-MPs may reflect thrombotic burden in AMI patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.